Given the current lack of strategies to treat EP300-mutant cancers such as Adult T-cell Leukemia Lymphoma, this study paves the way towards uncovering new therapeutic venues based on our identification of novel molecular pathways dysregulated primarily in the absence of EP300. The gene discussed is EP300; the disease is cancer.